A Study of MK-2060 in Healthy Participants (MK-2060-016)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-15

Study Completion Date

2025-04-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

NCT02608970

Thrombosis

COMPLETED PHASE1

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

NCT03196206

Thrombosis

COMPLETED PHASE1

Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

NCT00067093

Deep Vein Thrombosis

COMPLETED PHASE3

A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

NCT06355258

COVID 19 Associated Coagulopathy

RECRUITING PHASE1

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects

NCT02949206

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Panel A: MK-2060 IV (20 minutes)

Participants will receive a single dose of MK-2060 via intravenous (IV) infusion over 20 minutes on Day 1.

Group Type EXPERIMENTAL

MK-2060

Intervention Type BIOLOGICAL

Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Panel B: MK-2060 IV (10 minutes)

Participants will receive a single dose of MK-2060 via IV infusion over 10 minutes on Day 1.

Group Type EXPERIMENTAL

MK-2060

Intervention Type BIOLOGICAL

Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Panel C: MK-2060 IV (5 minutes)

Participants will receive a single dose of MK-2060 via syringe over 5 minutes on Day 1.

Group Type EXPERIMENTAL

MK-2060

Intervention Type BIOLOGICAL

Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Panel D: MK-2060 IV (2.5 minutes)

Participants will receive a single dose of MK-2060 via syringe over 2.5 minutes on Day 1.

Group Type EXPERIMENTAL

MK-2060

Intervention Type BIOLOGICAL

Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Panel E: MK-2060 IV (1 minute)

Participants will receive a single dose of MK-2060 via syringe over 1 minute on Day 1.

Group Type EXPERIMENTAL

MK-2060

Intervention Type BIOLOGICAL

Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Placebo

Participants will receive a single dose of saline via IV infusion or syringe over MK-2060-matched time period on Day 1.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK-2060

Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Intervention Type BIOLOGICAL

Placebo

Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is in good health before randomization
* Has a body mass index (BMI) between ≥18 and ≤32 kg/m\^2, inclusive

Exclusion Criteria

* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* Has a history of cancer

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes